300亿！增长19.4%！波士顿科学最新季报

思宇MedTech10-24

2024年10月23日，波士顿科学公布第三季度财报数据，业绩超出了普遍预期，公司再次上调了2024年预期。公司首席执行官Mike Mahone还在第三季度财报电话会议上表示，波士顿科学公司预计将在今年第四季度完成对Axonics的收购。#财报详情2024年第三季度净销售额为42.09亿美元（合约299.7亿人民币），同比增长19.4%。报告基础、运营基础和有机基础的增长率分别为19.5%和...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2477507354?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-10-24 17:32","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2477507354","market":"us","top_or_hot":-1,"title":"300亿！增长19.4%！波士顿科学最新季报","media":"思宇MedTech","content":"<div>\n<p>2024年10月23日，波士顿科学公布第三季度财报数据，业绩超出了普遍预期，公司再次上调了2024年预期。公司首席执行官Mike Mahone还在第三季度财报电话会议上表示，波士顿科学公司预计将在今年第四季度完成对Axonics的收购。#财报详情2024年第三季度净销售额为42.09亿美元（合约299.7亿人民币），同比增长19.4%。报告基础、运营基础和有机基础的增长率分别为19.5%和...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241024180636a1e6a7c7&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>300亿！增长19.4%！波士顿科学最新季报</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n300亿！增长19.4%！波士顿科学最新季报\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-24 17:32 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241024180636a1e6a7c7&s=b><strong>思宇MedTech</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2024年10月23日，波士顿科学公布第三季度财报数据，业绩超出了普遍预期，公司再次上调了2024年预期。公司首席执行官Mike Mahone还在第三季度财报电话会议上表示，波士顿科学公司预计将在今年第四季度完成对Axonics的收购。#财报详情2024年第三季度净销售额为42.09亿美元（合约299.7亿人民币），同比增长19.4%。报告基础、运营基础和有机基础的增长率分别为19.5%和...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241024180636a1e6a7c7&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0882574055.USD","symbol_name":"富达全球健康医疗A ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241024180636a1e6a7c7&s=b","article_id":"2477507354","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241024180636a1e6a7c7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2477507354","pubTimestamp":1729762333,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"2024年10月23日，波士顿科学公布第三季度财报数据，业绩超出了普遍预期，公司再次上调了2024年预期。#财报详情2024年第三季度净销售额为42.09亿美元，同比增长19.4%。报告基础、运营基础和有机基础的增长率分别为19.5%和18.2%。有机增长率为7.7%，显示出稳定的市场需求。有机增长率为24.6%，反映出该部门的强劲表现。第四季度预计净销售额增长范围为16.5%至18.5%，有机增长范围为14%至16%。预计2024年GAAP每股收益在1.28至1.30美元之间，调整后每股收益在2.45至2.47美元之间。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0882574055.USD":"富达全球健康医疗A ACC","LU0823417737.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","LU2087625088.SGD":"ALLSPRING  US ALL CAP GROWTH \"A\" (SGDHDG) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0251132253.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","BK4581":"高盛持仓","BK4504":"桥水持仓","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2242649171.HKD":"FIDELITY FUNDS GLOBAL THEMATIC OPPORTUNITIES \"A\" (HKD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BSX":"波士顿科学","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0187121727.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) INC","LU0238689110.USD":"贝莱德环球动力股票基金","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2244417387.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) ACC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU0048584097.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) INC","LU1153585028.USD":"BGF GLOBAL LONG-HORIZON EQUITY  \"A4\" (USD) INC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0950375773.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC A","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","BK4082":"医疗保健设备","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","LU0823417653.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","BK4588":"碎股"},"translate_title":"30 billion! An increase of 19.4%! Boston Scientific Latest Quarterly Report","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BSX":1},"content_text":"2024年10月23日，波士顿科学公布第三季度财报数据，业绩超出了普遍预期，公司再次上调了2024年预期。公司首席执行官Mike Mahone还在第三季度财报电话会议上表示，波士顿科学公司预计将在今年第四季度完成对Axonics的收购。#财报详情2024年第三季度净销售额为42.09亿美元（合约299.7亿人民币），同比增长19.4%。报告基础、运营基础和有机基础的增长率分别为19.5%和18.2%。与公司指导范围(13%至15%)相比，表现超出预期。GAAP净收入为4.69亿美元，每股收益(EPS)为0.32美元。调整后的每股收益为0.63美元，较去年同期的0.50美元有所增长。GAAP每股收益低于公司指导范围(0.36至0.38美元)。各业务部门表现医疗外科(Medsurg)：2024Q3净销售额为14.79亿美元，2023Q3净销售额为13.41亿美元，净销售额增长10.3%，运营基础增长10.4%。有机增长率为7.7%，显示出稳定的市场需求。内窥镜业务：由AXIOS™和Exalt D™这两款主力产品实现两位数增长，内腔手术业务实现强劲的两位数增长。泌尿业务：在结石管理和前列腺健康领域实现了两位数的增长，包括Rezum™和SpaceOAR™都实现了两位数的增长。LithoVue™ Elite和Tenacio™ Pump与AMS™ 700设备的推出持续推动了增长。神经调控业务：脑部业务实现了低两位数的增长，这一增长得益于美国市场本季度末的强劲表现。疼痛业务在运营上实现了两位数增长，而在有机基础上实现了低单位数增长。心血管(Cardiovascular)：2024Q3净销售额为27.31亿美元，2023Q3净销售额为21.85美元，净销售额增长25.0%，运营基础增长25.1%。有机增长率为24.6%，反映出该部门的强劲表现。心血管业务：介入心脏病治疗部门的业务增长了近15%，得益于美国AGENT™的强劲表现以及AVVIGO™+平台在全球的持续采用。结构性心脏病瓣膜部门实现了两位数的增长，这一增长由ACURATE Neo2™产品推动。WATCHMAN：在美国和日本继续转向使用WATCHMAN FLXTM Pro。心脏节律管理：诊断部门的增长达到了高单位数，由LUX-Dx II™/II+™植入式心脏监护器推动。电生理：FARApulse™设备治疗了超过125000名患者。外周介入治疗：药物洗脱产品组合继续实现两位数的增长；介入肿瘤学和栓塞部门实现了两位数的增长。地区销售增长美国市场净销售额增长23.5%，表现强劲。该地区的增长主要得益于新产品的推出和市场需求的增加。欧洲、中东和非洲(EMEA)地区净销售额增长15.2%，运营基础增长14.3%。该地区的增长受到新产品批准和市场扩展的推动。亚太地区(APAC)净销售额增长12.1%，拉丁美洲及加拿大(LACA)增长9.0%。这些地区的增长反映了公司在全球市场的持续扩展。# 最新动态FARAWAVEIM NAV消融导管获得FDA批准用于治疗阵发性房颤，FARAVIEWIM软件也获得510(k)批准。当前一代INGEVITY™+ 起搏导线的适应症扩大获批，新的适应症包括在连接到单腔或双腔起搏器时，对左束支区域（LBBA）进行传导系统起搏（CSP）和传感。用于长期监测心律失常的LUX-Dx II/II+™ 插入式心脏监护系统获得CE 标志。最近在《脊柱杂志》上发表的一项研究分析表明，与单独的标准护理（例如药物治疗）相比，在五年的随访中Intracept™ 骨内神经消融系统是一种经济有效的椎源性慢性腰痛治疗方法）。完成对Silk Road Medical, Inc.的收购，增强了在颈动脉疾病领域的产品组合。在日本获得FARAPULSE PFA系统的PMDA批准，进一步拓展市场。# 未来展望预计2024年全年净销售额增长约16.5%，有机增长约15%。第四季度预计净销售额增长范围为16.5%至18.5%，有机增长范围为14%至16%。预计2024年GAAP每股收益在1.28至1.30美元之间，调整后每股收益在2.45至2.47美元之间。# 获奖的医疗器械公司榜单全球手术机器人行业大奖2024全球医疗技术创新奖2024全球医疗科技新锐奖2024全球创新医疗器械奖2024#海外医疗器械大厂们美敦力Medtronic｜强生J&JMedTech｜雅培Abbott｜西门子医疗Siemens Healthineers｜飞利浦Philips Medical｜史赛克Stryker｜GE医疗GE Healthcare｜波士顿科学Boston Scientific｜依视路ESSILOR｜爱尔康Alcon｜蔡司医疗Carl Zeiss#中国医疗器械大厂们迈瑞医疗Mindray｜乐普医疗Lepu Medical|微创医疗MicroPort｜威高集团Weigao|联影医疗United Imaging","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2477507354"}